HUP0401121A2 - Csökkentett immunogenitású, módosított trombopoietin (TPO) - Google Patents
Csökkentett immunogenitású, módosított trombopoietin (TPO)Info
- Publication number
- HUP0401121A2 HUP0401121A2 HU0401121A HUP0401121A HUP0401121A2 HU P0401121 A2 HUP0401121 A2 HU P0401121A2 HU 0401121 A HU0401121 A HU 0401121A HU P0401121 A HUP0401121 A HU P0401121A HU P0401121 A2 HUP0401121 A2 HU P0401121A2
- Authority
- HU
- Hungary
- Prior art keywords
- modified
- thrombopoietin
- subject
- polypeptides
- reduced immunogenicity
- Prior art date
Links
- 102000036693 Thrombopoietin Human genes 0.000 title abstract 7
- 108010041111 Thrombopoietin Proteins 0.000 title abstract 7
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A találmány tárgyát olyan polipeptidek képezik, amelyek - elsősorbanterápiás célból - speciálisan embereknek adagolhatók. A találmányszerinti polipeptidek módosított polipeptidek, mely módosításeredményeként a polipeptid - embereknek történő adagolása esetén -kevésbé hajlamos immunreakció kiváltására. Közelebbről, a találmánytárgyát humán trombopoietin (TPO) módosított változatai képezik, melyTPO-proteinváltozatok in vivo alkalmazáskor lényegében nem immunogénekvagy kevésbé immunogének, mint a megfelelő, módosítás nélküli alakjuk.Szintén a találmány tárgyát képezik a nem módosított proteinbőlszármazó T-sejt-epitóp peptidek, valamint azok alkalmazása csökkentimmunogenitású, módosított trombopoietin-változatok előállítására. Atalálmány tárgyát képezik továbbá a találmány szerinti módosítotttrombopoietin-molekulákat kódoló DNS-ek, a találmány szerintimódosított trombopoietin-molekulákat tartalmazó gyógyászatikészítmények, valamint eljárások a módosított trombopoietin-molekulákelőállítására. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01104702 | 2001-02-26 | ||
| PCT/EP2002/001931 WO2002068469A2 (en) | 2001-02-26 | 2002-02-22 | Modified thrombopoietin with reduced immunogenicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0401121A2 true HUP0401121A2 (hu) | 2004-09-28 |
| HUP0401121A3 HUP0401121A3 (en) | 2006-01-30 |
Family
ID=8176606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401121A HUP0401121A3 (en) | 2001-02-26 | 2002-02-22 | Modified thrombopoietin with reduced immunogenicity |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040071688A1 (hu) |
| EP (1) | EP1364011A2 (hu) |
| JP (1) | JP2004533812A (hu) |
| KR (1) | KR20030077632A (hu) |
| CN (1) | CN1494590A (hu) |
| BR (1) | BR0207542A (hu) |
| CA (1) | CA2439168A1 (hu) |
| HU (1) | HUP0401121A3 (hu) |
| MX (1) | MXPA03007625A (hu) |
| PL (1) | PL363520A1 (hu) |
| RU (1) | RU2003127409A (hu) |
| WO (1) | WO2002068469A2 (hu) |
| ZA (1) | ZA200307468B (hu) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1636261B1 (en) * | 2003-06-26 | 2007-08-01 | MERCK PATENT GmbH | Thrombopoietin proteins with improved properties |
| US7879318B2 (en) | 2006-01-23 | 2011-02-01 | Mcw Research Foundation, Inc. | Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand |
| EP2167528B1 (en) * | 2007-06-21 | 2018-01-10 | Angelica Therapeutics, INC. | Modified toxins |
| WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
| EP2390261A4 (en) * | 2009-01-20 | 2012-11-14 | Hanall Biopharma Co Ltd | MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND METHOD FOR THE PRODUCTION THEREOF |
| EP2968450A4 (en) | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | MODIFIED TOXINS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0668352A1 (en) * | 1994-02-14 | 1995-08-23 | Kirin Brewery Company, Ltd. | Protein having TPO activity |
| AU4658596A (en) * | 1995-02-03 | 1996-08-21 | G.D. Searle & Co. | Novel c-mpl ligands |
-
2002
- 2002-02-22 US US10/469,101 patent/US20040071688A1/en not_active Abandoned
- 2002-02-22 CN CNA028055772A patent/CN1494590A/zh active Pending
- 2002-02-22 EP EP02726116A patent/EP1364011A2/en not_active Withdrawn
- 2002-02-22 KR KR10-2003-7010859A patent/KR20030077632A/ko not_active Application Discontinuation
- 2002-02-22 BR BR0207542-3A patent/BR0207542A/pt not_active IP Right Cessation
- 2002-02-22 PL PL02363520A patent/PL363520A1/xx unknown
- 2002-02-22 CA CA002439168A patent/CA2439168A1/en not_active Abandoned
- 2002-02-22 RU RU2003127409/13A patent/RU2003127409A/ru not_active Application Discontinuation
- 2002-02-22 JP JP2002567979A patent/JP2004533812A/ja not_active Withdrawn
- 2002-02-22 HU HU0401121A patent/HUP0401121A3/hu unknown
- 2002-02-22 WO PCT/EP2002/001931 patent/WO2002068469A2/en not_active Application Discontinuation
- 2002-02-22 MX MXPA03007625A patent/MXPA03007625A/es unknown
-
2003
- 2003-09-25 ZA ZA200307468A patent/ZA200307468B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2003127409A (ru) | 2005-04-10 |
| ZA200307468B (en) | 2004-07-02 |
| HUP0401121A3 (en) | 2006-01-30 |
| US20040071688A1 (en) | 2004-04-15 |
| JP2004533812A (ja) | 2004-11-11 |
| KR20030077632A (ko) | 2003-10-01 |
| PL363520A1 (en) | 2004-11-29 |
| WO2002068469A3 (en) | 2003-08-28 |
| MXPA03007625A (es) | 2003-12-04 |
| WO2002068469A2 (en) | 2002-09-06 |
| BR0207542A (pt) | 2004-03-09 |
| EP1364011A2 (en) | 2003-11-26 |
| CN1494590A (zh) | 2004-05-05 |
| CA2439168A1 (en) | 2002-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0401534A2 (hu) | Módosított humán IX. faktor | |
| HUP0400700A2 (hu) | Csökkentett immunogenitású, módosított humán agyi eredetű neutróf faktor (BDNF) | |
| NO20076239L (no) | Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom | |
| HUP0402071A2 (hu) | Csökkentett immunogenitású, módosított leptin | |
| IL156843A0 (en) | Combined use of factor vii polypeptides and factor viii polypeptides | |
| AU2003242305A1 (en) | Hla-a24-restricted cancer antigen peptide | |
| HUP0400313A2 (hu) | Új, biotechnológiai úton előállított, humán terápiára alkalmas szuperantigének | |
| HUP0203409A2 (hu) | Gamma-interferon-konjugátumok | |
| HUP0400703A2 (hu) | Csökkentett immunogenitású módosított eritropoietin (EPO) | |
| NO20015584L (no) | Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling | |
| WO2005116051A3 (de) | An mhc-moleküle bindende tumor-assoziierte peptide | |
| PL399137A1 (pl) | Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego | |
| WO2006081826A3 (en) | Survivin peptide vaccine | |
| PL371278A1 (en) | Modified factor viii | |
| HUP0400698A2 (hu) | Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA) | |
| HUP0303430A2 (hu) | Csökkentett immunogenitású, módosított protamin | |
| HUP0402334A2 (hu) | Módosított humán növekedési hormon | |
| HUP0401121A2 (hu) | Csökkentett immunogenitású, módosított trombopoietin (TPO) | |
| HUP0303309A2 (hu) | Csökkentett immunogenitású módosított interferon-alfa | |
| HUP0303150A2 (hu) | Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF) | |
| HUP0402041A2 (hu) | Csökkentett immunogenitású, módosított granulocita-kolonizációt stimuláló faktor (G-CSF) | |
| HUP0303310A2 (hu) | Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF) | |
| HUP0302566A2 (hu) | Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására | |
| HUP0303523A2 (hu) | Csökkentett immunogenitású, módosított inzulin | |
| WO2001036656A3 (en) | A complex between hyaluronic acid and a biomolecule and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |